Phase 1 Trial of CUDC-907



Subscribe to be notified of changes or updates to this page.

This study involves taking a study drug called CUDC-907. CUDC-907 is an oral drug that blocks certain proteins in tumor cells; these proteins may be important in the growth of some cancers. The overall goals of this study are to evaluate the side effects and benefits of CUDC-907 in patients with relapsed or treatment refractory solid tumor, brain tumor, or lymphoma, and to determine the best dose of CUDC-907 for children and adolescents. This study will also look at the levels of CUDC-907 in the blood over time after a dose.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at rodriguezc [at] or 267-426-9293.

Eligibility & Criteria

IRB #:
Official Title:
Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Study Phase:
Phase I
Eligible Age Range:
1 - 21 Years
Study Categories: